Compare Mentice AB with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
SEK 363 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.26
-34.37%
2.88
Revenue and Profits:
Net Sales:
71 Million
(Quarterly Results - Sep 2025)
Net Profit:
0 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-36.45%
0%
-36.45%
6 Months
-43.57%
0%
-43.57%
1 Year
-49.63%
0%
-49.63%
2 Years
-66.25%
0%
-66.25%
3 Years
-83.21%
0%
-83.21%
4 Years
-83.89%
0%
-83.89%
5 Years
-81.06%
0%
-81.06%
Mentice AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
12.58%
EBIT Growth (5y)
-191.90%
EBIT to Interest (avg)
-16.77
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.28
Sales to Capital Employed (avg)
1.86
Tax Ratio
30.67%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.76
EV to EBIT
-4.74
EV to EBITDA
-13.33
EV to Capital Employed
3.13
EV to Sales
0.95
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-66.05%
ROE (Latest)
-58.55%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
70.60
63.40
11.36%
Operating Profit (PBDIT) excl Other Income
6.50
-9.30
169.89%
Interest
0.30
0.40
-25.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-0.30
-17.60
98.30%
Operating Profit Margin (Excl OI)
-15.60%
-285.00%
26.94%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 11.36% vs 16.76% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 98.30% vs 36.00% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
290.30
273.60
6.10%
Operating Profit (PBDIT) excl Other Income
16.70
25.50
-34.51%
Interest
1.20
1.20
Exceptional Items
0.00
0.10
-100.00%
Consolidate Net Profit
-18.40
-2.80
-557.14%
Operating Profit Margin (Excl OI)
-47.80%
-8.00%
-3.98%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 6.10% vs 25.50% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -557.14% vs 90.88% in Dec 2023
About Mentice AB 
Mentice AB
Pharmaceuticals & Biotechnology
Mentice AB is a Sweden-based medical technology company. It provides software and hardware simulation solutions and related services for endovascular therapies. The Company’s solutions help healthcare professionals acquire, retain, and enhance their procedural skills. The Company’s solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. The Company also covers neurovascular, cardiovascular and peripheral interventions, among others. It is active globally.
Company Coordinates 
Company Details
Odinsgatan 10 , GOETEBORG NE : 411 03
Registrar Details






